European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

United Kingdom - English - myHealthbox

chiesi limited - felodipine - prolonged-release tablet - 5 mg - in the management of hypertension and prophylaxis of chronic stable angina pectoris

United Kingdom - English - myHealthbox

chiesi limited - felodipine - prolonged-release tablet - 10 mg - in the management of hypertension and prophylaxis of chronic stable angina pectoris

United Kingdom - English - myHealthbox

chiesi limited - salbutamol sulfate - modified release capsules, hard - 4.80mg - selective beta2 -adrenoceptor agonists for systemic use - continuous symptomatic treatment of asthma and other types of reversible obstructive airways disease

United Kingdom - English - myHealthbox

chiesi limited - salbutamol sulfate - modified release capsules, hard - 9.60mg - selective beta2 -adrenoceptor agonists for systemic use - continuous symptomatic treatment of asthma and other types of reversible obstructive airways disease

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 200 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; dilute hydrochloric acid - asthma trimbow 200/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - tobramycin - nebuliser solution - 300/4 milligram(s)/millilitre - other aminoglycosides; tobramycin

United Kingdom - English - myHealthbox

chiesi limited - beclometasone dipropionate, formoterol fumarate dihydrate. - pressurised inhalation solution. - 200/6 micrograms/metered dose - drugs for obstructive airway diseases; adrenergics, inhalants - fostair is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair is indicated in adults.

United Kingdom - English - myHealthbox

chiesi gmbh - dipropionate anhydrous, formoterol fumarate dihydrate. - inhalation powder. - 200 micrograms/6 micrograms for metered dose - rugs for obstructive airway diseases; adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics. - fostair nexthaler is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair nexthaler is indicated in adults. note: there are no relevant clinical data on the use of fostair nexthaler for the treatment of acute asthma attacks.

United States - English - NLM (National Library of Medicine)

chiesi usa, inc. - deferiprone (unii: 2bty8kh53l) (deferiprone - unii:2bty8kh53l) - ferriprox tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes. ferriprox tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with sickle cell disease or other anemias. - safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with diamond blackfan anemia. ferriprox is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulation. the following reactions have been reported in association with the administration of deferiprone: henoch-schönlein purpura; urticaria; and periorbital edema with skin rash [see adverse reactions (6.2)]. risk summary in animal reproduction studies, oral administration of deferiprone to pregnant rats and rabbits during organogenesis at doses 33% and 49%,